ReviewCancers2023
Ocular Complications of Radiotherapy in Uveal Melanoma.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.ESMO open · 2026Guideline
- Efficacy and safety of robotic Cyberknife radiotherapy in uveal melanoma: a systematic review and meta-analysis.Eye (London, England) · 2025Pooled it
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Clinical Classification of Radiation Maculopathy as a Predictor of Functional Response to Intravitreal Dexamethasone Implant.Journal of clinical medicine · 2026Article
- Significance of adjuvant external beam radiotherapy of the orbit in managing uveal melanoma with extraocular extension.BMJ open ophthalmology · 2026Article
- Early optical coherence tomography biomarkers of radiation maculopathy following ruthenium-106 brachytherapy for uveal melanoma in long-term follow-up.Journal of contemporary brachytherapy · 2026Article
- Unilateral Glaucoma as a Clinical Indicator of Iris and Ciliary Body Melanoma.Ocular oncology and pathology · 2026Article
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Gene therapy for uveal melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- A robot-assisted eye positioning method with high precision and repeatability for ocular particle therapy: mechanical and geometric assessment.Medical & biological engineering & computing · 2026Article
- Non-invasive prediction of the secondary enucleation risk in uveal melanoma based on pretreatment CT and MRI prior to stereotactic radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.Translational vision science & technology · 2026Article
- Descemet membrane endothelial keratoplasty in patients after radiation therapy for uveal melanoma.BMC ophthalmology · 2026Observational
- Article
- Comparison of MOLES and MelCancers · 2026Article
- Nanotherapeutic potential in glaucoma associated ocular cancers.Discover oncology · 2026Review
- Vitreoretinal Surgery for Intraocular Complications Following Radiotherapy Treatment of Uveal Melanoma.Cancers · 2025Article
- Outcomes Following Treatment with Notched Proton Beams for Peripapillary Choroidal Melanomas.Cancers · 2025Article
- Understanding and Exacerbating the Biological Response of Uveal Melanoma to Proton Beam Therapy.Cancers · 2025Review
- A Population-Based Study of Sex Differences in Cardiovascular Disease Mortality Among Adults with Ocular Cancer in the United States, 2000-2021.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma is the most common primary malignant intraocular tumor in adults. Radiation therapy has replaced enucleation and is now the preferred treatment in most cases. Nonetheless, around 70% of patients develop radiation-related complications, some of which are vision-threatening. The objective of this review is to present the most important complications associated with radiotherapy in the treatment of uveal melanoma and their pathogenesis, incidence, risk factors, and available preventive and therapeutic measures. The most common complications are cataracts, with a reported incidence ranging from 4% to 69%, and radiation retinopathy, reported in 5-68% of cases. Radiation-related complications are responsible for approximately half of secondary enucleations, the leading cause being neovascular glaucoma. A poor visual outcome is mainly associated with the presence of radiation retinopathy and radiation optic neuropathy. Therapeutic options are available for the majority of complications with the notable exception of optic neuropathy. However, many studies report a final visual acuity of less than 20/200 in more than 60% of treated eyes. Reducing complication rates can be achieved by lowering the dose of radiation, with the use of eccentric, customized plaques and careful planning of the irradiation delivery in order to protect structures vital to vision and by associating radiation therapy with other methods with the aim of reducing tumor volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.